PAPERS


**Ancillary Studies**


**Book Chapters**


**Letters**


**Abstracts & Presentations**


7. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): Design and early baseline results. Grimm RH, Jr, for the ALLHAT Research Group. (Presented at the 11th Asian-Pacific Congress of Cardiology; Bali, Indonesia; September 17-22, 1995.)

8. Design and Aims of the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Cushman WC. (Presented at the Panhellenic Congress on Arterial Hypertension; Greece, March 1, 1996.)


13. **The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): Recruitment update and baseline data.** Wright JT, Jr, Cutler JA, Davis BR, Cushman WC, Pressel S, for the ALLHAT Research Group. **Abstract:** Conference abstract monograph. (Presented at the 11th International Interdisciplinary Conference on Hypertension in Blacks; New Orleans, LA; July 14-17 1996.)

14. **Statistical design considerations for a large, simple trial of antihypertensive and lipid lowering treatments.** Davis B, Proschman M, Ford CE, for the ALLHAT Research Group. (Presented at the International Biometric Conference; Amsterdam, Netherlands; July 1-5, 1996.)

15. **Statistical issues in a large, simple trial of antihypertensive and lipid-lowering treatments.** Davis BR, Proschman M, Ford CE, for the ALLHAT Research Group. (Presented at the American Statistical Association Meeting; Chicago, IL; August 4-18, 1996.)

16. **Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): Update on Southeastern Clinical Research.** Cushman WC. (Presented at the 3rd Annual Meeting of the Consortium of Southeastern Hypertension Centers; Research Triangle Park, NC; August 15, 1996.)


18. **Newer vs. older drugs ± cholesterol lowering:** ALLHAT. Cutler J. (Presented at the WHO-ISH Collaboration Annual Meeting and Clinical Trials Symposium; St. Jean Cap Ferrat, France; May 1-3, 1997.) (No written material associated with this presentation.)


20. **The impact of external events on on-going clinical trials.** Davis BR, Sacks F, Alderman M, Thornquist M, DeMets DL. **Abstract:** Pending. (Presented at the 2nd Joint Meeting of the Society of Clinical Trials/International Society of Clinical Biostatistics; Boston, MA; July 6-10, 1997.)


22. **The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial, ALLHAT.** Oparil S. **Abstract:** Pending. (Presented at the 4th International Conference on Preventive Cardiology Satellite Symposium entitled, "Optimal Therapy in the Prevention of CAD"; Montreal, Quebec; June 29-July 3, 1997.)


30. Major Cardiovascular Events in Hypertensive Patients Randomized to Doxazosin vs Chlorthalidone: Preliminary Results from ALLHAT. The ALLHAT Collaborative Research Group. (Presented by C. Furbeg and BR Davis at the 49th Annual Scientific Session of the American College of Cardiology, Late-Breaking Clinical Trials in Interventional Cardiology (#72), ANAHEIM, CA, March 15, 2000 [10:45 am-12:15 pm].)


39. Cardiovascular disease rates in Hispanic and Caribbean hypertensives receiving doxazosin and chlorthalidone in the ALLHAT. Colon PJ, Wright JT, Ford CE, Cuttler JA, for the ALLHAT


52. ALLHAT results and future directions for hypertension research. Salive ME. (Presented at the American College of Preventive Medicine Meeting, February 22, 2003, San Diego, California.)

53. AHT Results. Wright J. (Presented at the Association of Black Cardiologist Meeting, March 30, 2003, Chicago, Illinois.)

54. LLT Results. Haywood J. (Presented at the Association of Black Cardiologist Meeting, March 30, 2003, Chicago, Illinois.)

55. ALLHAT: Results and implications in older ALLHAT patients. Williamson J. (Presented at the Society of Geriatric Cardiology Meeting, March 31, 2003, Chicago, Illinois.)

56. Cardiovascular disease (CVD) outcomes in hypertensive patients with impaired renal function.


60. The ANBP2 and ALLHAT. Cutler J, Barrett S. (Presented at the American Academy of Physician Assistants Meeting, May 26, 2003, New Orleans, Louisiana.)


62. How were step up drugs selected in ALLHAT. Cushman B. (Presented at the American Diabetes Association Meeting, June 16, 2003, New Orleans, Louisiana.)

63. ALLHAT vs. ANBP2. Cushman W. (Presented at the Southern Medical Association Meeting, June 28, 2003, Myrtle Beach, South Carolina.)

64. Subgroup analysis of blacks and diabetics. Wright J. (Presented at the National Medical Association Meeting, August 2-7, 2003, Philadelphia, Pennsylvania.)

65. ALLHAT and JNC 7. Probstfield J. (Presented at the European Society of Cardiology Meeting, August 30 - September 3, 2003, Vienna, Austria.)

66. ALLHAT: The Key Findings. Furberg C. (Presented at the 76th Annual Scientific Sessions of the American Heart Association, November 9-12, 2003, Orlando, Florida. Special Session I: ALLHAT Results and JNC-VII Recommendations.)

67. ALLHAT Results for Subgroups and Secondary Outcomes. Probstfield JL. (Presented at the 76th Annual Scientific Sessions of the American Heart Association, November 9-12, 2003, Orlando, Florida. Special Session I: ALLHAT Results and JNC-VII Recommendations.)

68. After NHANES, ALLHAT and JNC-VI: How Can We Implement the Findings? Whelton PK. (Presented at the 76th Annual Scientific Sessions of the American Heart Association, November 9-12, 2003, Orlando, Florida. Special Session I: ALLHAT Results and JNC-VII Recommendations.)
